An observational study in Fibromyalgia, sponsored by Bilecik Seyh Edebali Universitesi. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Bilecik Seyh Edebali Universitesi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 195 studies in Fibromyalgia with a site in Turkey — 51 open to participants now, 55 under way, none of them phase 3. Fibromyalgia · Turkey.
Among the 195 studies in Fibromyalgia with a site in Turkey, this one is the 17th largest by planned enrollment of the 91 observational ones that give a count, is one of 25 that started in 2026, is one of 91 observational ones, reaches primary completion later than 47 of the 54 other live ones, and was the 188th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →51 of the 195 studies in Fibromyalgia with a site in Turkey are open now. Recruiting first, the newest first:
Karabuk University · Sites in Turkey
Ages 18–65 · Women only · Healthy volunteers
Artvin Coruh University · Sites in Turkey
Ages 18+
Artvin Coruh University · Sites in Turkey
Ages 18+
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
Ankara Yildirim Beyazıt University · Sites in Turkey
Ages 18–65 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
195 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 100 across 279 observational studies indexed under Fibromyalgia.
Median enrollment 52 across the 104 interventional studies, 100 across the 91 observational. Of the 126 that completed or were terminated, 3 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 195 have an industry lead sponsor. The 10 most frequent:
Bilecik Seyh Edebali Universitesi is the lead sponsor of 63 studies on the registry; 28 are open to participants now.
Bilecik Seyh Edebali Universitesi has 2 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
18 of the studies in Fibromyalgia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07261696Nigde Omer Halisdemir UniversityThe Effects of Inspiratory Muscle Training Female Patients With Fibromyalgia | 2026-12-05 |
| NCT07403929Hacettepe UniversityThe Effect of Fermented Grape Juice Consumption on Fibromyalgia Patients | 2026-12-15 |
| NCT07326163Bilecik Seyh Edebali UniversitesiThe Effect of Peppermint Oil Aromatherapy on Pain, Functional Capacity and Cost in Fibromyalgia Patients | 2026-12-30 |
| NCT07878286Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyThe Role of Interoceptive Sensitivity in Central Sensitization Symptom Severity in Fibromyalgia | 2027-01-15 |
| NCT07830186Saglik Bilimleri UniversitesiQigong Intervention for Fibromyalgia | 2027-01-21 |
Add all 18 to your calendar (.ics) → With an account.
Among the 195 studies in Fibromyalgia with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to reveal the effects of pain catastrophizing, psychological resilience, and illness perception on the impact level of fibromyalgia in patients with fibromyalgia, to determine the predictive power of these psychosocial variables regarding the impact level of fibromyalgia, and to evaluate their roles in explaining the burden of the disease.
While pain catastrophizing, resilience, and illness perception have been examined separately in patients with fibromyalgia, studies evaluating the extent to which these variables collectively predict the impact of the disease are limited. Addressing pain catastrophizing and negative illness perception as risk factors, alongside resilience as a protective factor, within a single model will contribute to a more holistic explanation of the disease burden experienced by fibromyalgia patients. The results of this study are expected to enhance the understanding of the psychosocial factors that determine the impact of the disease on fibromyalgia patients. Furthermore, the findings are anticipated to provide a scientific basis for the development of psychoeducation, cognitive-behavioral counseling, resilience-supporting interventions, and individualized care plans by nurses and other healthcare professionals. In this regard, the study will contribute to strengthening the biopsychosocial approach to fibromyalgia management and to the planning of patient-centered care practices.
Patients diagnosed with fibromyalgia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Visual Analog Scale
VAS (Visual Analog Scale): A scale consisting of a 10 cm horizontal line marked at equal intervals, with one end representing "no pain" and the other "unbearable pain." The patient is asked to mark the point on the line that best represents the intensity of their pain. This distance, measured in millimeters, is interpreted as a "score." Regarding pain intensity, a score of 0 is rated as "no pain," while a score of 10 is rated as "unbearable, worst possible pain."
Time frame: 1 days
Revised Fibromyalgia Impact Questionnaire
Revised Fibromyalgia Impact Questionnaire (FIQR): This questionnaire was updated by Bennett et al. in 2009. It consists of 21 separate questions, all rated on a scale of 0 to 10; a score of 10 represents the worst possible state, while 0 indicates the absence of the complaint. The questionnaire comprises three sub-dimensions: "function" (9 questions), "overall impact" (2 questions), and "symptoms" (10 questions). The total score for function (range 0-90) is divided by 3, the total score for overall impact (range 0-20) remains unchanged, and the total score for symptoms (range 0-100) is divided by 2. The total questionnaire score (0-100) is the sum of these values. A higher score indicates a high level of impact from the disease. The recommended cut-off points for disease severity are as follows: 0-23, remission; 24-40, mild disease; 41-63, moderate disease; 64-82, severe disease; and 83-100, very severe disease. The Cronbach's alpha for the FIQR is 0.95, and item-total correlations ra
Time frame: 1 days
The Pain Catastrophizing Scale
The Pain Catastrophizing Scale is a 13-item self-report scale developed by Sullivan et al. to assess the extent to which individuals tend to catastrophize in response to pain; it utilizes a 5-point Likert-type rating system (scoring 0-4). The original form of the scale comprises three sub-dimensions: helplessness, magnification, and rumination. The internal consistency reliability of the Turkish adaptation of the Pain Catastrophizing Scale was found to be very high, with a Cronbach's alpha coefficient of 0.955. Item-total and inter-item correlation coefficients for the scale were determined to range between 0.488 and 0.848.
Time frame: 1 days
Brief Illness Perception Questionnaire
Brief Illness Perception Questionnaire: Developed by Broadbent et al. in 2006. This scale comprises 8 items plus an additional item investigating causal factors. With the exception of the ninth item regarding causal factors, the eight items on the scale use a Likert-type scoring system ranging from 0 to 10. The first five items assess cognitive illness representations: consequences (Item 1), timeline (Item 2), personal control (Item 3), treatment control (Item 4), and identity (Item 5). Two items assess emotional illness perceptions: concern (Item 6) and emotions (Item 8). One item evaluates illness coherence (Item 7). Causal representation is assessed via an open-ended question asking patients to list the most important causal factors of their illness (Item 9). Scores on the scale indicate the perceived threat of the illness or the individual's level of ease regarding the condition. When calculating the score, the values for items 3, 4, and 7 are reversed and added to the scores of
Time frame: 1 days
Brief Resilience Scale
Brief Resilience Scale: This scale was developed by Smith et al. (2008) to measure individuals' psychological resilience. It is a 6-item, self-report instrument using a 5-point Likert scale. Items 2, 4, and 6 are reverse-coded. After reversing the scores for these items, high total scores indicate a high level of psychological resilience. The internal consistency reliability of the Turkish adaptation of the scale was found to be .83.
Time frame: 1 days
Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bilecik Seyh Edebali Universitesi